Tetracycline Hydrochloride (Page 3 of 3)

OVERDOSAGE

In case of overdosage, discontinue medication, treat symptomatically and institute supportive measures. Tetracycline is not dialyzable.

DOSAGE AND ADMINISTRATION

Adults

Usual daily dose, 1 gram as 500 mg b.i.d. or 250 mg q.i.d. Higher doses such as 500 mg q.i.d. may be required for severe infections or for those infections which do not respond to the smaller doses.

Children above eight years of age

Usual daily dose, 10 to 20 mg/lb (25 to 50 mg/kg) body weight divided in four equal doses.

Therapy should be continued for at least 24 to 48 hours after symptoms and fever have subsided.

For treatment of brucellosis, 500 mg tetracycline q.i.d. for three weeks should be accompanied by streptomycin, 1 gram intramuscularly twice daily the first week and once daily the second week.

For the treatment of syphilis in patients allergic to penicillin, the following dosage of tetracycline is recommended: early syphilis (less than one year’s duration)-500 mg q.i.d. for 15 days. Syphilis of more than one year’s duration (except neurosyphilis)-500 mg q.i.d. for 30 days.

For treatment of gonorrhea, the recommended dose is 500 mg by mouth four times a day for seven days.

In cases of moderate to severe acne which, in the judgement of the clinician, require long-term treatment, the recommended initial dosage is 1 gram daily in divided doses. When improvement is noted, dosage should be gradually reduced to maintenance levels ranging from 125 mg to 500 mg daily. In some patients it may be possible to maintain adequate remission of lesions with alternate-day or intermittent therapy. Tetracycline therapy of acne should augment the other standard measures known to be of value. Duration of long-term treatment which can safely be recommended has not been established (see WARNINGS and Carcinogenicity, Mutagenicity, Impairment of Fertility).

Concomitant therapy

Absorption of tetracycline is impaired by antacids containing aluminum, calcium or magnesium and preparations containing iron, zinc, or sodium bicarbonate.

Food and some dairy products also interfere with absorption.

In the treatment of streptococcal infections, a therapeutic dose of tetracycline should be administered for at least ten days.

In patients with renal impairment (see WARNINGS): total dosage should be decreased by reduction of recommended individual doses and/or by extending time intervals between doses.

Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis: 500 mg, by mouth, four times a day for at least seven days.

Administration of adequate amounts of fluid with the capsule formulation of tetracycline is recommended to wash down the drug and reduce the risk of esophageal irritation and ulceration (see ADVERSE REACTIONS).

HOW SUPPLIED

Tetracycline Hydrochloride Capsules USP, 250 mg are available as orange opaque and yellow opaque capsules, imprinted with company logo and 2416, containing 250 mg of tetracycline hydrochloride, packaged in:

bottles of 20 NDC 54868-0024-7
bottles of 30 NDC 54868-0024-3
bottles of 40 NDC 54868-0024-1
bottles of 60 NDC 54868-0024-4
bottles of 90 NDC 54868-0024-8
bottles of 100 NDC 54868-0024-5

Tetracycline Hydrochloride Capsules USP, 500 mg are available as black and yellow capsules, imprinted with company logo and 2407, containing 500 mg of tetracycline hydrochloride, packaged in:

bottles of 20bottles of 30 NDC 54868-0025-9NDC 54868-0025-1
bottles of 40 NDC 54868-0025-3
bottles of 60 NDC 54868-0025-4
bottles of 90 NDC 54868-0025-7
bottles of 100 NDC 54868-0025-5

PHARMACIST: Dispense in a tight, light resistant container as defined in the USP, with a child-resistant closure (as required).

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

ANIMAL PHARMACOLOGY AND ANIMAL TOXICOLOGY

Hyperpigmentation of the thyroid has been produced by members of the tetracycline class in the following species: in rats by oxytetracycline, doxycycline, minocycline, tetracycline PO4 and methacycline; in minipigs by doxycycline, minocycline, tetracycline PO4 and methacycline; in dogs by doxycycline and minocycline; in monkeys by minocycline.

Minocycline, tetracycline PO4, methacycline, doxycycline, tetracycline base, oxytetracycline HCI and tetracycline HCI were goitrogenic in rats fed a low iodine diet. This goitrogenic effect was accomplished by high radioactive iodine uptake. Administration of minocycline also produced a large goiter with high radioiodine uptake in rats fed a relatively high iodine diet.

Treatment of various animal species with this class of drugs has also resulted in the induction of thyroid hyperplasia in the following: in rats and dogs (minocycline), in chickens (chlortetracycline) and in rats and mice (oxytetracycline). Adrenal gland hyperplasia has been observed in goats and rats treated with oxytetracycline.

TEVA PHARMACEUTICALS USA

Sellersville, PA 18960

Rev. A 6/2009

Relabeling and Repackaging by:
Physicians Total Care, Inc.
Tulsa, OK 74146

PRINCIPAL DISPLAY PANEL

Tetracycline HCl 250mg package label
(click image for full-size original)

TETRACYCLINE HYDROCHLORIDE

Capsules USP

250 mg

Rx only

PRINCIPAL DISPLAY PANEL

Tetracycline HCl 500mg package label
(click image for full-size original)

TETRACYCLINE HYDROCHLORIDE

Capsules USP

500 mg

Rx only

TETRACYCLINE HYDROCHLORIDE tetracycline hydrochloride capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:54868-0024(NDC:0172-2416)
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
TETRACYCLINE HYDROCHLORIDE (TETRACYCLINE) TETRACYCLINE HYDROCHLORIDE 250 mg
Inactive Ingredients
Ingredient Name Strength
SILICON DIOXIDE
STARCH, CORN
STEARIC ACID
FD&C YELLOW NO. 6
D&C YELLOW NO. 10
TITANIUM DIOXIDE
Product Characteristics
Color orange (orange opaque) , yellow (yellow opaque) Score no score
Shape CAPSULE Size 19mm
Flavor Imprint Code 2416
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:54868-0024-1 40 CAPSULE (CAPSULE) in 1 BOTTLE None
2 NDC:54868-0024-3 30 CAPSULE (CAPSULE) in 1 BOTTLE None
3 NDC:54868-0024-4 60 CAPSULE (CAPSULE) in 1 BOTTLE None
4 NDC:54868-0024-5 100 CAPSULE (CAPSULE) in 1 BOTTLE None
5 NDC:54868-0024-7 20 CAPSULE (CAPSULE) in 1 BOTTLE None
6 NDC:54868-0024-8 90 CAPSULE (CAPSULE) in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA060704 03/01/1988
TETRACYCLINE HYDROCHLORIDE tetracycline hydrochloride capsule
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:54868-0025(NDC:0172-2407)
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
TETRACYCLINE HYDROCHLORIDE (TETRACYCLINE) TETRACYCLINE HYDROCHLORIDE 500 mg
Inactive Ingredients
Ingredient Name Strength
SILICON DIOXIDE
STARCH, CORN
STEARIC ACID
FD&C BLUE NO. 1
FD&C RED NO. 40
D&C YELLOW NO. 10
TITANIUM DIOXIDE
Product Characteristics
Color black, yellow Score no score
Shape CAPSULE Size 22mm
Flavor Imprint Code 2407
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:54868-0025-1 30 CAPSULE (CAPSULE) in 1 BOTTLE None
2 NDC:54868-0025-3 40 CAPSULE (CAPSULE) in 1 BOTTLE None
3 NDC:54868-0025-4 60 CAPSULE (CAPSULE) in 1 BOTTLE None
4 NDC:54868-0025-5 100 CAPSULE (CAPSULE) in 1 BOTTLE None
5 NDC:54868-0025-7 90 CAPSULE (CAPSULE) in 1 BOTTLE None
6 NDC:54868-0025-9 20 CAPSULE (CAPSULE) in 1 BOTTLE, PLASTIC None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANDA ANDA060704 10/09/1996
Labeler — Physicians Total Care, Inc. (194123980)
Establishment
Name Address ID/FEI Operations
Physicians Total Care, Inc. 194123980 relabel, repack

Revised: 03/2010 Physicians Total Care, Inc.

Page 3 of 3 1 2 3

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2024. All Rights Reserved.